{"name":"Aragon Pharmaceuticals, Inc.","slug":"aragon-pharmaceuticals-inc","ticker":"","exchange":"","domain":"aragon.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ADT (Standard of Care)","genericName":"ADT (Standard of Care)","slug":"adt-standard-of-care","indication":"Metastatic hormone-sensitive prostate cancer","status":"phase_3"},{"name":"ARN-509","genericName":"ARN-509","slug":"arn-509","indication":"Metastatic castration-resistant prostate cancer","status":"phase_2"}]}],"pipeline":[{"name":"ADT (Standard of Care)","genericName":"ADT (Standard of Care)","slug":"adt-standard-of-care","phase":"phase_3","mechanism":"ADT (Androgen Deprivation Therapy) suppresses testosterone production or blocks androgen receptor signaling to inhibit growth of androgen-dependent prostate cancer cells.","indications":["Metastatic hormone-sensitive prostate cancer","Locally advanced prostate cancer (in combination with radiation therapy)","Biochemically recurrent prostate cancer"],"catalyst":""},{"name":"ARN-509","genericName":"ARN-509","slug":"arn-509","phase":"phase_2","mechanism":"ARN-509 is an androgen receptor inhibitor.","indications":["Metastatic castration-resistant prostate cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPZWFwMUJ2dzZvRUlFLUI3blNkbTFtWWoxRmFnNjRyellTdUZ5S1hNVm8yTXcyWDRHeXYyekdPSDZGdUFpVEcxcmdsMW0yX2VwbGMydGJWdFN6WDgwMDFGckFRdHdyTG1qRGwtSkQxangyOElYenFWZV9SNjk4aTlZejk0MmQ?oc=5","date":"2025-04-28","type":"pipeline","source":"Insightace Analytic","summary":"SERD Therapeutics Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"SERD Therapeutics Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQSzVTM1VUelpGQzFYVHA5MUNreGxfRUlXZjl3UFRZaXRXckNJT2dyU0w5bExWeGxkVHZSZmVjcF8yVV9mZlRaSzhqaGdLRVAxczJIQlVUdG1ZMnNTa3pQdGdtb0k5VVBWQklqeUd3R3VQZGlSdnN4QS1VejZxZTZHY2gxOXR2Nkc2WHN1OHR3?oc=5","date":"2024-03-07","type":"pipeline","source":"Frontiers","summary":"Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient - Frontiers","headline":"Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxNekplNUVFVWcwdVVpVXl4ZVc0c2djVFR5X0lPMEFORTgwbFlZdVpuaVZtMmZSY2g0OFJ4WHNENHE3NlJUVUZRUnBMQTMxMXZUSFdHUkJZaWpCU3dEbXAtSkVmVEVfQmYzeHFlNnU3dElERVQ3NklZX0RNNTV1LVZIeVAwQlB4WGdHNXRRQnZUeTJfR2swRlhXWGpMazNDeTI4MkU5VmY0TENkVFVVa0dsdzV0QWIwUWNtXy1RUXVLX2oteldZYTJzWS05a0ZNdlEydzYyU3k5VjBreEJMdWJseUF3aFJfbWdNRFR5cVZOVUU0bGY5X0JhbmpQWFh5VlotalU0Q0wwYVdTZWFfaDhXRFh5UnJQOHh0Q1FfbldEMWljR2s?oc=5","date":"2023-10-23","type":"pipeline","source":"Business Wire","summary":"1859 Strengthens Leadership with Appointment of Consulting CSO and Strategic Pharma Advisors, Bringing Deep Oncology and Immunology Expertise - Business Wire","headline":"1859 Strengthens Leadership with Appointment of Consulting CSO and Strategic Pharma Advisors, Bringing Deep Oncology and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPTjI0by1pUHB4bGFmcWRaTHVxa3dFUDZGdUVuRVc4aTEwVzBsX2tqeldmbGpDd19abW5FelRRdEJ5ZkYtTUg2YllxNHVUZm9ON1Y1YzkyalFHMDNUeEF2QkdacDdwakEzQnl1UTJDOTNZaVh4SmJqVzc0cnh5bEoxM1ZqY0dCUUtVbGZOUWZBR1JiNmxPN3NpVTA0X0QySG5zRzZJQnhnekhaZzk4Q29HR1pjZnA0ZWtIbjdlZVotWVlibnNKTUE?oc=5","date":"2022-08-15","type":"pipeline","source":"European Medical Journal","summary":"Advancing Patient Care in the Evolving Prostate Cancer Treatment Landscape - European Medical Journal","headline":"Advancing Patient Care in the Evolving Prostate Cancer Treatment Landscape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPckk3UGhtSkpQWnRzYXpHTGcySVBmVVZKY096aEEza1ZVNm81QWktcjMyZ19fbTFYcmM5aE5PQ0hTS1NnM0thcUdKZ2VrSlJFZ3dtdWNqTkFWWVk3d1FFOVRDYzlRNzRZM214Zk9rTXpsUThsS0s0TzI5aEN5Q25RWm5sZkIxQjJ0ZFE?oc=5","date":"2022-05-30","type":"pipeline","source":"Pearce IP","summary":"“Method of” treating in the prior art not distinguishable from a “method for” treating - Pearce IP","headline":"“Method of” treating in the prior art not distinguishable from a “method for” treating","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNTUpmZlgxbzdxUWFKbVI2VS1wcG8wOVdjSzJzc284QXV0Smg1WnByNFBrN0U5NHRVQVk2SER5ZHZSREx2M1JOWXBLWHByTFh1MjRhbU1ua09hb3RQUU1TTTN2RXdhMzl2ZDFVcDVRVUFiUVJmakFCVVJBM2c4RDJlNm1PczRHeExTZzY3TzhWOA?oc=5","date":"2020-01-10","type":"deal","source":"Fierce Biotech","summary":"Roche taps Amunix's tech in $40M non-cancer R&D deal - Fierce Biotech","headline":"Roche taps Amunix's tech in $40M non-cancer R&D deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNeVRuZkgwcVcxMVFtVXRvVElMZnF5RWdSMHNkeldGWmR0V1NlRFR3YVhDR2hLaWJUVy1MWDk3RDU1VF9od3lPamhNejhKRF9iUFBVOW1oTGVRcmVYeVd5d3d5SU9HVXBxSGhQYy15ZjhfX3RPd09rM0UwbUFSWWtEN292S1pRV3pCTThUYTNKMUdwdlo3VGhoWG05RWN1RTdj?oc=5","date":"2018-09-25","type":"pipeline","source":"BioSpace","summary":"Scientist.com Adds Experienced Drug Hunter Mark Herbert to Management Team - BioSpace","headline":"Scientist.com Adds Experienced Drug Hunter Mark Herbert to Management Team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPRldKdlE4cm9PY2R5bVBzZ2V0QmdVMGp3UXRpdm05ZkNra21NeUx3cjcyT2l0RzZ6SFZpUTY3U2loTHNCWVNxbmF0ZjBzb0NzbFN5TnVPNFY4WjZtTEhEdEt0N2hBNU1MclFDeDBLWDJkTWJpS3otbFdPcXJJODU2OGhFclQ5c0RFWEdKNWdXQnNvbEpKa3ZoNHE1VkR0MnN2WUN4Qjc1cllha0hFRndpeFlYSV9YUWlK?oc=5","date":"2015-12-03","type":"deal","source":"BioPharma Dive","summary":"Can Rich Heyman score a buyout hat-trick with prostate cancer drug startup ORIC? - BioPharma Dive","headline":"Can Rich Heyman score a buyout hat-trick with prostate cancer drug startup ORIC?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPMnBTR3BLVElYTjBWcGFwV0NMM0pZM2xaTE8xaWxRTkpCRkF5UlQ3Q3hXS0RIcWlfVDZmX0c4dF9WUGt3Z2xLcExqaDVhLXVMeFpRLWljeWkyX0U2dlB5WUstV29SYXdILTlraUV5d1dKclpFcE43TThGeW9BaExkNG9LTDk3bXRmUWdkOG5jM3BuSG5BeWd6TXpHYUFhc01GWG1vaE5TTG1sWWxPS3JtTk1n?oc=5","date":"2014-12-05","type":"pipeline","source":"Salk Institute for Biological Studies","summary":"Salk Institute Board of Trustees welcomes biotech entrepreneur Richard Heyman - Salk Institute for Biological Studies","headline":"Salk Institute Board of Trustees welcomes biotech entrepreneur Richard Heyman","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQbWRURklBQUNSNVdib3ZZOEhEeDMwM2VTSEZqWkd2VWFTVVIyLTFCQnFqSEV1SFFxakE5cVlseExkenpRM2NvcEVVa2hBRDhzRmZCMUI1S3Y2Q0dvUlAyM3lGRHFYUThoMVV3MkVzNTdPeWFHMkN3OWdWY3QtcjBmdzZEbE9kdzR6VFVrRTJFcWVNYVlUTFRaQTUybzlfemxtUjZkVlJHYzZBUVVLS2xuRTRvSQ?oc=5","date":"2014-07-02","type":"deal","source":"Reuters","summary":"Roche to buy U.S. biotech firm Seragon for up to $1.7 billion - Reuters","headline":"Roche to buy U.S. biotech firm Seragon for up to $1.7 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNLUVVX19kSFJYcy1nY2t3QlVXaGhZVkNqRXNyWmdyMHZyc1ZUWEVBRm9EdmZuTjF0eHo2c0tsU1dBcTVHRlFUM2IxU29SLVphYUthaWhIQVJnMFJoeVBpVW5YTVE0bVZHTFZrZFZYWDVjR1ltOGI4Z3NBYkJHTE1GY3Y5d01XSlVnR25CektWOUUyZHFSRkNJOEFaRHdzVXdnOTNMQmxZYWc5S0tEQlFmckhPYVdCcXFOUU9PS1Q5MzU4Tzg?oc=5","date":"2013-06-19","type":"pipeline","source":"Technology Networks","summary":"Aragon Pharmaceuticals Announces Acquisition by Johnson & Johnson - Technology Networks","headline":"Aragon Pharmaceuticals Announces Acquisition by Johnson & Johnson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPNS1QNmREUTZtLWRxdkVIUjYzVFR1eThvSXM3Wk5tS1o5RnZmU1c4SG52cV80T243TnNCZWpxX1M2dzg2VmhLbU91OUtPN1A1WldhS0NNcWhKV2RKeUhDRHdTLUdqdmVLSEU4bk51RlV4Z3UyQlhEMFk5OWlTdDg5ampqMUMtaWhqQTlxY3FUZ0JETlN4?oc=5","date":"2012-09-27","type":"pipeline","source":"San Diego Union-Tribune","summary":"BIOTECH: Aragon Pharmaceuticals raises $50M - San Diego Union-Tribune","headline":"BIOTECH: Aragon Pharmaceuticals raises $50M - San Diego Union","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}